Terms: = Germ cell tumor AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
1906 results:
1. Two sisters diagnosed with familial paraganglioma syndrome type 1 (FPGL1) and multiple endocrine neoplasia type 2A (men2a).
Stawarz K; Durzynska M; Galazka A; Paszkowska M; Bienkowska-Pluta K; Zwolinski J; Tysarowski A; Kwiatkowska E; Podgorska A
World J Surg Oncol; 2024 May; 22(1):139. PubMed ID: 38802890
[TBL] [Abstract] [Full Text] [Related]
2. [Neurofibromatosis type 1 associated with pheochromocytoma: a case report with a brief review of the literature].
Lugovskaya AY; Britvin TA; Gurevich LE; Rog IS; Nefedova LN; Ilovayskaya IA
Probl Endokrinol (Mosk); 2023 Sep; 70(2):53-64. PubMed ID: 38796761
[TBL] [Abstract] [Full Text] [Related]
3.
Prabhash K; Saldanha E; Patil V; Bal M; Reddy P S; Sanjeev A; Kumar R; Poojary D; Noronha V; Menon N; Mittal N; Trivedi V; Nambiar K; Mishra R; Tanwar N; Malhotra R; Pange P; Gupta V; Veldore VH; Chougule A; Chaturvedi P; Dutt A; Chandrani P
JCO Precis Oncol; 2024 May; 8():e2300622. PubMed ID: 38754058
[TBL] [Abstract] [Full Text] [Related]
4. Patient-reported outcomes with selpercatinib treatment in patients with ret-driven cancers in the phase I/II LIBretTO-001 trial.
Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM
ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381
[TBL] [Abstract] [Full Text] [Related]
5. Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B.
Réti Z; Tabák ÁG; Garami M; Kalina I; Kiss G; Sápi Z; Tóth M; Tőke J
JCO Precis Oncol; 2024 May; 8():e2300675. PubMed ID: 38709988
[TBL] [Abstract] [Full Text] [Related]
6. Clinical, Morphological and Molecular Features of Spitz tumors.
Donati M; Mansour B; Hagstrom M; Gerami P; Kazakov DV
Cesk Patol; 2024; 60(1):35-48. PubMed ID: 38697826
[TBL] [Abstract] [Full Text] [Related]
7. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract] [Full Text] [Related]
8. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
9. Accelerated men2a in homozygous ret carriers in the context of consanguinity.
Machens A; Dralle H
Eur J Endocrinol; 2024 Mar; 190(3):K43-K46. PubMed ID: 38465999
[TBL] [Abstract] [Full Text] [Related]
10. Molecular classification and tumor microenvironment characteristics in pheochromocytomas.
Qin S; Xu Y; Yu S; Han W; Fan S; Ai W; Zhang K; Wang Y; Zhou X; Shen Q; Gong K; Sun L; Zhang Z
Elife; 2024 Feb; 12():. PubMed ID: 38407266
[TBL] [Abstract] [Full Text] [Related]
11. The role of prophylactic parathyroidectomy during thyroidectomy for MTC in patients with men2a syndrome.
Kavazis C; Romanidis K; Pitiakoudis M; Kesisoglou I; Laskou S; Sapalidis K
Folia Med (Plovdiv); 2023 Oct; 65(5):720-727. PubMed ID: 38351753
[TBL] [Abstract] [Full Text] [Related]
12. ret kinase inhibitors for the treatment of ret-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract] [Full Text] [Related]
13. Updates on the genetics of multiple endocrine neoplasia.
Sahakian N; Castinetti F; Romanet P; Reznik Y; Brue T
Ann Endocrinol (Paris); 2024 Apr; 85(2):127-135. PubMed ID: 38325596
[TBL] [Abstract] [Full Text] [Related]
14. Thyroid Cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
15. [Intestinal ganglioneuromatosis as an early extra-endocrine manifestation of type 2B multiple endocrine neoplasia].
Averianova JV; Kalinchenko NY; Brovin DN; Petryaykina EE; Tiulpakov AN
Probl Endokrinol (Mosk); 2023 Jun; 69(6):109-112. PubMed ID: 38312000
[TBL] [Abstract] [Full Text] [Related]
16. [A Case Report of Multiple Endocrine Neoplasia Type 2A(men2a)Diagnosed with Medullary Thyroid Carcinoma].
Morikawa N; Yoshitomi S; Shimabara M; Tatara N; Hara K; Ikeda E; Tsuji H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1780-1782. PubMed ID: 38303205
[TBL] [Abstract] [Full Text] [Related]
17. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci.
Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and safety of pralsetinib in Chinese advanced ret-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
19. An audit of medullary thyroid carcinoma from a tertiary care hospital in northwest India.
Chakraborty AM; Rai A; Pal R; Mukherjee S; Dahiya D; Kumar R; Saikia UN; Panda NK; Bhadada SK; Dutta P
Front Endocrinol (Lausanne); 2023; 14():1226348. PubMed ID: 38260132
[TBL] [Abstract] [Full Text] [Related]
20. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T; Machlah YM; Führer D
Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
[TBL] [Abstract] [Full Text] [Related]
[Next]